Retraction: Mechanisms and effects of curcumin on spatial learning and memory improvement in APPswe/PS1dE9 mice (Journal of Neuroscience Research, (2014), 92, 2, (218-231), 10.1002/jnr.23322);Mechanisms and effects of curcumin on spatial learning and memory improvement in APPswe/PS1dE9 mice

Journal of Neuroscience Research

Volumn 92, Issue 2, 2014, Pages 218-231

  Wang, Pengwen ^a,b   Su, Caixin ^c   Li, Ruisheng ^d   Wang, Hong ^e   Ren, Ying ^a,b   Sun, Haiyun ^a,b   Yang, Jinduo ^a,b   Sun, Jianning ^f   Shi, Jing ^a   Tian, Jinzhou ^a   Jiang, Shucui ^c  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b State Administration of Traditional Chinese Medicine   (China)

^c MCMASTER UNIVERSITY   (Canada)

^d XINJIANG MEDICAL UNIVERSITY   (China)

^e Amcare Women and Children's Specialized Health   (China)

^f State Administration of Traditional Chinese Medicine   (China)

Author keywords

APPswe PS1dE9 double transgenic mice; Curcumin; Insulin degrading enzyme; Morris water maze test; Presenilin 2

Indexed keywords

AMYLOID BETA PROTEIN; CURCUMIN; GAMMA SECRETASE; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; PRESENILIN 2; ROSIGLITAZONE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; HIPPOCAMPAL CA1 REGION; LOW DRUG DOSE; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPATIAL LEARNING; SPATIAL MEMORY; TRANSGENIC MOUSE; WESTERN BLOTTING;

APPSWE/PS1DE9 DOUBLE TRANSGENIC MICE; AΒ40 AND AΒ42; CURCUMIN; INSULIN-DEGRADING ENZYME; MORRIS WATER MAZE TEST; PRESENILIN-2;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CURCUMIN; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MAZE LEARNING; MEMORY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 84890099421     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.24580     Document Type: Erratum

References (56)

1. Ahmed T, Gilani AH. 2009. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacol Biochem Behav 91:554-559.
2. Baum L, Cheung SK, Mok VC, Lam LC, Leung VP, Hui E, Ng CC, Chow M, Ho PC, Lam S, Woo J, Chiu HF, Goggins W, Zee B, Wong A, Mok H, Cheng WK, Fong C, Lee JS, Chan MH, Szeto SS, Lui VW, Tsoh J, Kwok TC, Chan IH, Lam CW. 2007. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res 56:509-514.
3. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V. 2008. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28:110-113.
4. Beckmann N, Gérard C, Abramowski D, Cannet C, Staufenbiel M. 2011. Noninvasive magnetic resonance imaging detection of cerebral amyloid angiopathy-related microvascular alterations using superparamagnetic iron oxide particles in APP transgenic mouse models of Alzheimer's disease: application to passive Abeta immunotherapy. J Neurosci 31:1023-1031.
5. Borenstein AR, Copenhaver CI, Mortimer JA. 2006. Early-life risk factors for Alzheimer disease. Alzheimer Dis Assoc Disord 20:63-72.
6. Brenn A, Grube M, Jedlitschky G, Fischer A, Strohmeier B, Eiden M, Keller M, Groschup MH, Vogelgesang S. 2013. St. John's wort reduces beta-amyloid accumulation in a double transgenic Alzheimer's disease mouse model-role of P-glycoprotein. Brain Pathol doi: 10.1111/bpa.12069.
7. Calcul L, Zhang B, Jinwal UK, Dickey CA, Baker BJ. 2012. Natural products as a rich source of tau-targeting drugs for Alzheimer's disease. Future Med Chem 4:1751-1761.
8. Chandra V, Pandav R, Dodge HH, Johnston JM, Belle SH, DeKosky ST, Ganguli M. 2001. Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology 57:985-989.
9. Citron M. 2000. Secretases as targets for the treatment of Alzheimer's disease. Mol Med Today 6:392-397.
10. Darvesh AS, Carroll RT, Bishayee A, Novotny NA, Geldenhuys WJ, Van der Schyf CJ. 2012. Curcumin and neurodegenerative diseases: a perspective. Expert Opin Invest Drugs 21:1123-1140.
11. Davinelli S, Sapere N, Zella D, Bracale R, Intrieri M, Scapagnini G. 2012. Pleiotropic protective effects of phytochemicals in Alzheimer's disease. Oxid Med Cell Longev 2012:386527.
12. Elvang AB, Volbracht C, Pedersen LO, Jensen KG, Karlsson JJ, Larsen SA, Mork A, Stensbol TB, Bastlund JF. 2009. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. J Neurochem 110:1377-1387.
13. Escribano L, Simon AM, Perez-Mediavilla A, Salazar-Colocho P, Del Rio J, Frechilla D. 2009. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 379:406-410.
14. Ganguli M, Chandra V, Kamboh MI, Johnston JM, Dodge HH, Thelma BK, Juyal RC, Pandav R, Belle SH, DeKosky ST. 2000. Apolipoprotein E polymorphism and Alzheimer disease: the Indo-US Cross-National Dementia Study. Arch Neurol 57:824-830.
15. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP. 2006. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24:516-524.
16. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ. 2007. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102:1095-1104.
17. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL. 2006. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63:168-174.
18. Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamagi U, Sawchak S. 2010. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 30:131-146.
19. Hamaguchi T, Ono K, Yamada M. 2010. Review: curcumin and Alzheimer's disease. CNS Neurosci Ther 16:285-297.
20. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. 2008. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65:1631-1652.
21. Herholz K. 2008. Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease. Eur J Nucl Med Mol Imag 35(Suppl 1):S25-S29.
22. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM. 2004. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18:902-904.
23. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. 2004. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13:159-170.
24. Jenny NS. 2012. Inflammation in aging: cause, effect, or both? Discov Med 13:451-460.
25. Kapakos G, Youreva V, Srivastava AK. 2012. Cardiovascular protection by curcumin: molecular aspects. Indian J Biochem Biophys 49:306-315.
26. Lal R, Lin H, Quist AP. 2007. Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. Biochim Biophys Acta 1768:1966-1975.
27. Lim JE, Song M, Jin J, Kou J, Pattanayak A, Lalonde R, Fukuchi K. 2012. The effects of MyD88 deficiency on exploratory activity, anxiety, motor coordination, and spatial learning in C57BL/6 and APPswe/PS1dE9 mice. Behav Brain Res 227:36-42.
28. Lyck L, Jelsing J, Jensen PS, Lambertsen KL, Pakkenberg B, Finsen B. 2006. Immunohisto-chemical visualization of neurons and specific glial cells for stereological application in the porcine neocortex. J Neurosci Methods 152:229-242.
29. McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, Santini VE, Lee HS, Kubilus CA, Stern RA. 2009. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 68:709-735.
30. Miners JS, Barua N, Kehoe PG, Gill S, Love S. 2011. Aβ-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 70:944-959.
31. Morris RG. 1981. Spatial localization does not depend on the presence of local cues. Learn Motiv 12:239-260.
32. Morris RG, Garrud P, Rawlins JN, O'Keefe J. 1982. Place navigation impaired in rats with hippocampal lesions. Nature 297:681-683.
33. Narasingappa RB, Javagal MR, Pullabhatla S, Hltoo HH, Rao JK, Hernandez JF, Govitrapong P, Vincent B. 2012. Activation of α-secretase by curcumin-aminoacid conjugates. Biochem Biophys Res Commun 424:691-696.
34. O'Reilly JA, Lynch M. 2012. Rosiglitazone improves spatial memory and decreases insoluble Abeta1-42 in APP/PS1 mice. J Neuroimmune Pharmacol 7:140-144.
35. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. 2006. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199:265-273.
36. Placanica L, Tarassishin L, Yang G, Peethumnongsin E, Kim SH, Zheng H, Sisodia SS, Li YM. 2009. Pen2 and presenilin-1 modulate the dynamic equilibrium of presenilin-1 and presenilin-2 gamma-secretase complexes. J Biol Chem 284:2967-2977.
37. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. 2005. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2:131-136.
38. Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, Montine TJ, Cummings JL, Cole GM. 2012. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther 4:43.
39. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD, Roziglitazone in Alzheimer's Disease Study Group. 2006. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6:246-254.
40. Shirotani K, Edbauer D, Prokop S, Haass C, Steiner H. 2004. Identification of distinct gamma-secretase complexes with different APH-1 variants. J Biol Chem 279:41340-41345.
41. Shirotani K, Tomioka M, Kremmer E, Haass C, Steiner H. 2007. Pathological activity of familial Alzheimer's disease-associated mutant presenilin can be executed by six different gamma-secretase complexes. Neurobiol Dis 27:102-107.
42. Thomas P, Fenech M. 2007. A review of genome mutation and Alzheimer's disease. Mutagenesis 22:15-33.
43. Viswanathan A, Greenberg SM. 2011. Cerebral amyloid angiopathy in the elderly. Ann Neurol 70:871-880.
44. Walsh DM, Selkoe DJ. 2007. A beta oligomers-a decade of discovery. J Neurochem 101:1172-1184.
45. Wang P, Jiang S, Cui Y, Yue Z, Su C, Sun J, Sheng S, Tian J. 2011. The n-terminal 5-MER peptide analogue P165 of amyloid precursor protein exerts protective effects on SH-SY5Y cells and rat hippocampus neuronal synapses. Neuroscience 173:169-178.
46. Watson GS, Craft S. 2003. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 17:27-45.
47. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S. 2005. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13:950-958.
48. Wei QY, Chen WF, Zhou B, Yang L, Liu ZL. 2006. Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochim Biophys Acta 1760:70-77.
49. Woods JA, Wilund KR, Martin SA, Kistler BM. 2012. Exercise, inflammation and aging. Aging Dis 3:130-140.
50. Xiong Z, Hongmel Z, Lu S, Yu L. 2011. Curcumin mediates presenilin-1 activity to reduce beta-amyloid production in a model of Alzheimer's disease. Pharmacol Rep 63:1101-1108.
51. Yanagisawa D, Taguchi H, Yamamoto A, Shirai N, Hirao K, Tooyama I. 2011. Curcuminoid binds to amyloid-β1-42 oligomer and fibril. J Alzheimers Dis 24(Suppl 2):33-42.
52. Yang C, Su X, Liu A, Zhang L, Yu A, Xi Y, Zhai G. 2013. Advances in clinical study of curcumin. Curr Pharm Des 19:1966-1973.
53. Yoshida H, Okumura N, Nishimura Y, Kitagishi Y, Matsuda S. 2011. Turmeric and curcumin suppress presenilin 1 protein expression in Jurkat cells. Exp Ther Med 2:629-632.
54. Zhang C, Browne A, Child D, Tanzi RE. 2010. Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem 285:28472-28480.
55. Zhao YL, Ma XB, Han WD. 2006. Basic laboratory techniques in molecular biology. Beijing: Qinghua University Publishing House.
56. Zhou H, Beevers CS, Huang S. 2011. The targets of curcumin. Curr Drug Targets 12:332-347.